⚡️Breaking: Replimune wins FDA approval
Endpoints News
@endpts
The biopharma world is here. Get the industry’s most comprehensive daily news reports at endpts.com/subscribe
- Tarsus is paying $450M upfront for Alkeus and its Phase 3 Stargardt pill, its second acquisition in two months as smaller commercial biotechs join this year's M&A run.
- Intellia traced the worst liver enzyme spikes in its CRISPR ATTR trials to a single genetic marker, giving it a way to flag at-risk patients before dosing.
- The FDA approved Moderna's flu vaccine mFlusiva, six months after Vinay Prasad's CBER refused to even review the application and set off a public fight with the company.
- Braveheart Bio priced an upsized $383M IPO to push a Hengrui-licensed heart drug into Phase 3, where it would compete with Bristol Myers and Cytokinetics.
